How much funding has Siolta Therapeutics raised?

Siolta Therapeutics has raised $88.5M in total funding, most recently a Series C round.

Who are Siolta Therapeutics's investors?

Siolta Therapeutics's investors include Capital Group, Khosla Ventures.

When was Siolta Therapeutics founded?

Siolta Therapeutics was founded in 2016.

Where is Siolta Therapeutics headquartered?

Siolta Therapeutics is headquartered in San Francisco Bay Area, California, United States.

What industry is Siolta Therapeutics in?

Siolta Therapeutics operates in Biotech, Healthcare, Medical.

How many employees does Siolta Therapeutics have?

Siolta Therapeutics has 11-50 employees.

Siolta Therapeutics

San Francisco Bay Area, United States · Founded 2016 · $88.5M raised

Biotech

Healthcare

Medical

Headquarters: San Francisco Bay Area, California
Employees: 11–50
Founded: 2016
Business Model: B2B

Website: sioltatherapeutics.com
Total Funding: $88.5M
Last Round: $12.0M Series CMar 2024
Rounds: 4

About

Siolta Therapeutics is a clinical-stage biotech company developing live biotherapeutic products (LBPs) targeting inflammatory and allergic diseases through manipulation of the human microbiome. Their proprietary Precision Symbiotics Platform designs multi-strain microbial consortia to prevent conditions such as atopic dermatitis and food allergy in newborns. Founded as a UCSF spinout, their lead program STMC-103H has received FDA Fast Track Designation.

Summary

Siolta Therapeutics is a Biotech company based in San Francisco Bay Area, United States, founded in 2016. It has raised $88.5M in total across 4 rounds, most recently a $12.0M Series C round in Mar 2024. Investors include Capital Group and Khosla Ventures.

LinkedIn X (Twitter)